What changed in Twist Bioscience Corporation's latest annual report
In the year ended 30 Sep 2025, Twist Bioscience Corporation's total liabilities rose 19.3% to USD 168.90m, from USD 141.63m; cash and cash equivalents fell 19.1% to USD 183.05m, from USD 226.32m; total assets rose 4.5% to USD 641.86m, from USD 614.32m.
Year ended 30 Sep 2025. Source: 10-K filed 17 Nov 2025, read it on SEC EDGAR.
USD 141.63m to USD 168.90m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Net income | -208.73m | -77.67m | Not comparable |
| Total assets | 614.32m | 641.86m | Up 4.5% |
| Total liabilities | 141.63m | 168.90m | Up 19.3% |
| Cash and cash equivalents | 226.32m | 183.05m | Down 19.1% |
| Shareholders' equity | 472.69m | 472.96m | Up 0.1% |
Questions people ask
Is Twist Bioscience Corporation profitable?
Not in its latest year: it reported a net loss of USD 77.67m in the year ended 30 Sep 2025. The year before: a net loss of USD 208.73m.
How much cash and debt does Twist Bioscience Corporation have?
At its latest year end (30 Sep 2025), Twist Bioscience Corporation reported cash and cash equivalents of USD 183.05m.
Where do these numbers come from?
From Twist Bioscience Corporation's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Twist Bioscience Corporation?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Amgen Inc.Net income up 88.5%
- Gilead Sciences, Inc.Net income up 1672.9%
- Moderna, Inc.Revenue down 39.9%
- Revolution Medicines, Inc.Total liabilities up 146.7%
- Biogen Inc.Net income down 20.8%
- Exelixis IncCash and cash equivalents up 122%
- Neurocrine Biosciences IncCash and cash equivalents up 206%
- Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%